Investigation Launched Against Viatris Inc. Over Alleged Securities Law Violations
New York, NY / March 13, 2025 / – Levi & Korsinsky, a leading securities law firm, announced today that it has commenced an investigation of Viatris Inc. (NASDAQ: VTRS) over potential securities laws violations. The investigation comes in the wake of the company’s fourth quarter and full year 2024 financial results press release, issued on February 27, 2025.
Financial Results Miss Consensus Estimates
Viatris reported fourth-quarter revenue of $3.1 billion, which fell short of the consensus estimate of $3.2 billion. The company also missed earnings per share estimates, reporting $0.95 per share compared to the consensus estimate of $1.01 per share. Full-year revenue came in at $12.6 billion, below the consensus estimate of $12.7 billion. Earnings per share for the year were $3.71, below the consensus estimate of $3.83 per share.
Levi & Korsinsky’s Investigation
Levi & Korsinsky’s investigation focuses on whether Viatris and certain of its officers or directors violated securities laws by making false and/or misleading statements and/or failing to disclose material information to investors. Specifically, the investigation concerns whether the company and its executives provided false or misleading information to investors about Viatris’ financial condition and prospects.
Implications for Investors
If it is determined that Viatris and its executives engaged in securities fraud or other violations of law, investors may be able to recover their losses through a class action lawsuit. The lead plaintiff in such a lawsuit would be represented by Levi & Korsinsky free of charge. The investigation is ongoing, and investors who purchased Viatris securities between certain dates are encouraged to contact the firm.
Global Impact
The implications of this investigation extend beyond Viatris and its investors. The pharmaceutical industry as a whole may face increased scrutiny as a result of this investigation. The pharmaceutical sector has been under pressure in recent years due to rising drug prices and increased regulatory scrutiny. This investigation could further erode investor confidence in the sector and lead to increased regulatory oversight.
Conclusion
The investigation into Viatris Inc. is an important development for investors in the pharmaceutical sector. If it is determined that the company and its executives violated securities laws, investors may be able to recover their losses. Additionally, the investigation could lead to increased regulatory scrutiny of the pharmaceutical industry as a whole. Levi & Korsinsky will continue to closely monitor the situation and provide updates to investors as more information becomes available.
- Levi & Korsinsky announces investigation of Viatris Inc.
- Investigation focuses on potential securities laws violations.
- Investors encouraged to contact the firm if they purchased Viatris securities.
- Implications for investors and the pharmaceutical industry.
